REMICADE BIOSIMILARS MARKET ANALYSIS

Remicade Biosimilars Market, by Disease Indication (Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Others), and by Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI1769
Formats :
Excel and PDF
Industry : Biotechnology

Remicade Biosimilars MarketSize and Trends

Market Dynamics

Increasing incidence of autoimmune diseases such as plaque psoriasis and rheumatoid arthritis are expected to drive growth of the Remicade biosimilar market size. According to the American Autoimmune Related Disease Association, around 50 million American suffered from autoimmune diseases in the U.S. in 2017. Moreover, faster reaction rates of these biosimilars due to their availability in the form of intravenous mode of administration is further expected to increase the adoption of Remicade biosimilar over the forecast period. Furthermore, patent expiry of the branded versions is expected to increase the number of biosimilars for its branded counterparts thereby increasing the demand for Remicade biosimilar. However, stringent regulatory guidelines for development of these biosimilars as well as side effects of these drugs leading to risk of hospitalization are expected to restrain growth of the global Remicade biosimilar market.